Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David G Kallend"'
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco, Frederick J Raal
Publikováno v:
American Journal of Preventive Cardiology, Vol 13, Iss , Pp 100403- (2023)
Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agen
Externí odkaz:
https://doaj.org/article/0011f94e522840b59e2bf9b7e51e40ab
Autor:
Kausik K, Ray, Frederick J, Raal, David G, Kallend, Mark J, Jaros, Wolfgang, Koenig, Lawrence A, Leiter, Ulf, Landmesser, Gregory G, Schwartz, David, Lawrence, Andrew, Friedman, Lorena, Garcia Conde, R Scott, Wright
Publikováno v:
European Heart Journal. 44:129-138
Background Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce03820390aa437070e0fe443fecce18
https://doi.org/10.1093/eurheartj/ehac594
https://doi.org/10.1093/eurheartj/ehac594
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R S Wright, yanntong chiang, Lorena Garcia Conde Orozco, Frederick J Raal
Publikováno v:
Circulation. 144
Introduction: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent with twice-yearly subcutaneous dosing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bf8ebd576ca1bb752a82b9d686da779
https://doi.org/10.1161/circ.144.suppl_1.11143
https://doi.org/10.1161/circ.144.suppl_1.11143
Autor:
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Frederick J Raal, Kausik K Ray, Gregory G Schwartz, yanntong chiang, Lorena Garcia Conde Orozco, R S Wright
Publikováno v:
Circulation. 144
Introduction: Disorders of glucose metabolism increase in prevalence globally and contribute to excess risk of ASCVD, necessitating intensive lipid lowering. Aim: To analyze efficacy and safety of inclisiran (small interfering RNA targeting hepatic P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d06f4fab4e54bb0e131fe95ab2b42147
https://doi.org/10.1161/circ.144.suppl_1.11033
https://doi.org/10.1161/circ.144.suppl_1.11033
Autor:
Ulf Landmesser, David G. Kallend, Wolfgang Koenig, Lawrence A. Leiter, Frederick J. Raal, Kausik Kumar Ray, Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco
Publikováno v:
Journal of the American College of Cardiology. 79:1555
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f60099e0b4374f6ffe90be867c44cae
https://doi.org/10.1016/s0735-1097(22)02546-3
https://doi.org/10.1016/s0735-1097(22)02546-3
Autor:
Yohan Bossé, Marie-Ève Paré, Éric Jubinville, David G Kallend, Maude Talbot, Mathieu C. Morissette, Michaël Maranda-Robitaille, Sophie Aubin, Mélanie Hamel-Auger, Benoit J. Arsenault, Marie-Josée Beaulieu, Jean-Christophe Bérubé
Publikováno v:
The European respiratory journal. 50(3)
Reverse lipid transport is critical to maintain homeostasis. Smoking causes lipid accumulation in macrophages, therefore suggesting suboptimal reverse lipid transport mechanisms. In this study, we investigated the interplay between smoking and revers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a978e2ce4b0d3316f62f81a788826af
https://pubmed.ncbi.nlm.nih.gov/28889112
https://pubmed.ncbi.nlm.nih.gov/28889112
Autor:
James D. Otvos, Matthijs Moerland, Bela F. Asztalos, H. Kempen, David G. Kallend, S. Eralp Bellibas, Elias J. Jeyarajah, Peter L.J. Wijngaard
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 36(4)
Objective— To determine effects of single ascending doses of MDCO-216 on high-density lipoprotein (HDL) subfractions in relation to changes in cholesterol efflux capacity in healthy volunteers and in patients with stable angina pectoris. Approach a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37090890cb9c02f1bf92e3d3d085a0e
https://pubmed.ncbi.nlm.nih.gov/26916733
https://pubmed.ncbi.nlm.nih.gov/26916733